IMUGEN Reference Diagnostic Division
Oxford Immunotec, Inc. d/b/a IMUGEN
315 Norwood Park South, Norwood MA 02062 • [redacted]

Lyme Antibody Analysis

Submitter:

WOODSON C MERRELL MD
SUITE 1B
44 EAST 67TH STREET
NEW YORK, NY 10065

Ordering Provider: WOODSON C MERRELL MD

Account #: MERW

Patient:

Name: JEFFREY EPSTEIN
Address: 9 EAST 71ST STREET
NEW YORK, NY 10021

D.O.B.: 01/20/1953

Submitter Record #:

IMUGEN Patient #: 2018013061

Antibody Capture Enzyme Immunoassay

Test Date: 09/17/2018

Antigen	Antibody Isotype	Results PLASMA # 13081 Collection Date: 09/14/2018 Receipt Date: 09/17/2018	Results CSF # Collection Date: Receipt Date:
B. burgdorferi 49736	IgM	<1	
	IgG	<1	
	IgA	<1	

Values reflect the relative amount of *B. burgdorferi*-specific antibody corrected for background.
Normal Range: no antibody detected at <0.8 for IgM and <1 for IgG and IgA.

Comments: No IgM, IgG or IgA antibody to *B. burgdorferi* detected by capture EIA; the IgG immunoblot results fall within normal limits.

Interpretation: No serologic evidence of infection with *B. burgdorferi* (Lyme).

Immunoblot IgG (Western Blot)

PLASMA # 13061
Test Date: 09/17/2018



Reactive bands are listed in kD of *B. burgdorferi* antigens with which IgG is reactive.
Normal Range: Reactivity to <5 antigens on each blot.

Note 1: Results should be evaluated in conjunction with clinical presentation and other medical and diagnostic findings.
Note 2: A negative result does not exclude the possibility of infection with *Borrelia burgdorferi*. Antibodies may not yet be present at the time of blood sample collection or may not yet be detectable.
Note 3: If the initial LAA test result is negative (i.e. antibodies not detected) and the patient's clinical history strongly suggests infection, the collection of a second sample is strongly recommended.
Note 4: Quantitative antibody capture enzyme immunoassay values can vary two-fold within a test run. Values should not be considered clinically relevant outside of a comparative analysis performed on the same patient on the same test run.
Note 5: These tests were developed and their performance characteristics determined by IMUGEN. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. These tests are used for clinical purposes. They should not be regarded as investigational or for research.
Note 6: A positive result may not exclude the possibility of a successfully treated past infection.

Report Date: 09/17/2018 KEW/JAL

Mihae Platt M.D., Ph.D. Director
CLIA number 22D0650196